文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/CT 与全身 MRI 在多发性骨髓瘤中的诊断效能及管理影响比较

Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-19

本研究比较了初治多发性骨髓瘤患者中18F-FDG PET/CT与全身MRI(WBMRI)对骨病变的检出灵敏度及对治疗决策的影响。46例患者中,WBMRI每患者灵敏度为91.3%,高于PET/CT的69.6%;但两种影像加入临床数据后治疗决策差异无统计学意义(p=0.08)。

要点

  • WBMRI对骨病变的每患者灵敏度(91.3%)高于18F-FDG PET/CT(69.6%)。
  • 基于临床数据单独治疗比例为69.6%,加PET/CT升至87.0%(p=0.02),加WBMRI升至93.5%(p=0.002)。
  • PET/CT与WBMRI之间的治疗决策差异无统计学意义(p=0.08)。

核心结论

  • WBMRI对骨病变的每患者灵敏度高于18F-FDG PET/CT,但两者对治疗决策的影响无统计学差异,均可用于初治分期。

研究设计与样本

  • 回顾性比较46例初治多发性骨髓瘤患者,分别由核医学医师和放射科医师判读18F-FDG PET/CT与WBMRI的骨髓瘤骨病变。

主要发现

  • 18F-FDG PET/CT检出骨病变的每患者灵敏度为69.6%(32/46),单独PET组分为54.3%(25/46);WBMRI为91.3%(42/46)。
  • 27/46(58.7%)病例两种影像结果一致,19/46(41.3%)病例WBMRI检出更多局灶性骨病变。
  • 仅基于临床数据,32/46(69.6%)患者会接受治疗;加入PET/CT后升至40/46(87.0%)(p=0.02),加入WBMRI后升至43/46(93.5%)(p=0.002)。
  • PET/CT与WBMRI之间的治疗决策差异无统计学意义(p=0.08)。

关键数值与推荐

  • 骨病变依据国际骨髓瘤工作组(IMWG)标准及临床参考标准定义。
  • 采用McNemar检验比较基于临床评估±18F-FDG PET/CT或WBMRI的管理决策。

临床怎么用

  • 初治多发性骨髓瘤分期可根据当地设备可及性和专业经验选择18F-FDG PET/CT或WBMRI。
  • 两种影像加入临床数据后均提高治疗决策比例,但彼此间决策差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. METHODS: Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. RESULTS: Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). CONCLUSION: Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Westerland O, Amlani A, Kelly-Morland C, et al. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging. 2021. PMID: 33469686. doi:10.1007/s00259-020-05182-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。